Gyre Therapeutics (NASDAQ:GYRE) Trading Down 3% – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded down 3% on Tuesday . The company traded as low as $11.80 and last traded at $11.84. 40,221 shares were traded during mid-day trading, a decline of 46% from the average session volume of 74,921 shares. The stock had previously closed at $12.20.

Gyre Therapeutics Trading Down 2.5 %

The business has a 50-day moving average of $12.83 and a 200-day moving average of $12.62.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics in the second quarter worth $166,000. WINTON GROUP Ltd bought a new position in Gyre Therapeutics during the second quarter worth $220,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Gyre Therapeutics during the second quarter valued at about $218,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.